Phenazolam

Phenazolam
Clinical data
Trade names	None (designer drug)
Legal status
Legal status	CA: Schedule IV; DE: NpSG (Industrial and scientific use only); UK: Class C ; US: Unscheduled; Controlled in Serbia and Italy;
Pharmacokinetic data
Bioavailability	Unknown
Metabolism	Unknown
Elimination half-life	Unknown
Excretion	Unknown
Identifiers
	IUPAC name 8-bromo-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine;
CAS Number	87213-50-1 ;
PubChem CID	1032830;
ChemSpider	887985;
UNII	2AVB9ZZ4ZS;
ChEMBL	ChEMBL1451229;
CompTox Dashboard (EPA)	DTXSID10236191;
Chemical and physical data
Formula	C17H12BrClN4
Molar mass	387.67 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NN=C2N1C3=C(C=C(C=C3)Br)C(=NC2)C4=CC=CC=C4Cl;
	InChI InChI=1S/C17H12BrClN4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3; Key:BUTCFAZTKZDYCN-UHFFFAOYSA-N;

Clobromazolam (also known as phenazolam, DM-II-90, and BRN 4550445) is a synthetic benzodiazepine derivative. It is structurally related to other triazolobenzodiazepines and is believed to act as a potent sedative and hypnotic through positive allosteric modulation of the GABAA receptor. The compound was first described in the early 1980s during research into novel anxiolytic and hypnotic agents, but it was never developed or approved for medical use.^[2] Clobromazolam has emerged in the 21st century as a designer drug, being sold online and detected in forensic casework. It was first identified in seized samples by a Swedish laboratory in March 2016.^[3]^[4] Due to its high potency and lack of clinical evaluation, its use has been associated with significant safety concerns, including the risk of overdose, dependence, and severe central nervous system depression.